ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $11.81, but opened at $12.13. ABIVAX Société Anonyme shares last traded at $12.02, with a volume of 35,104 shares changing hands.
Analyst Ratings Changes
Several brokerages have recently commented on ABVX. Laidlaw assumed coverage on ABIVAX Société Anonyme in a report on Monday. They set a “buy” rating and a $48.00 price objective for the company. BTIG Research initiated coverage on shares of ABIVAX Société Anonyme in a research note on Monday, May 20th. They issued a “buy” rating and a $43.00 price target for the company. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, April 29th. They set a “buy” rating and a $50.00 price objective for the company. Piper Sandler initiated coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, Morgan Stanley upped their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, ABIVAX Société Anonyme has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.
Read Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Up 0.4 %
Institutional Investors Weigh In On ABIVAX Société Anonyme
A number of hedge funds and other institutional investors have recently modified their holdings of ABVX. Capstone Investment Advisors LLC bought a new position in ABIVAX Société Anonyme during the 4th quarter worth approximately $618,000. Commodore Capital LP bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth approximately $20,277,000. Blackstone Inc. purchased a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth $25,345,000. Franklin Resources Inc. bought a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $13,630,000. Finally, Great Point Partners LLC bought a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $16,585,000. Institutional investors own 47.91% of the company’s stock.
ABIVAX Société Anonyme Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
- Five stocks we like better than ABIVAX Société Anonyme
- What is the Dow Jones Industrial Average (DJIA)?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Profitably Trade Stocks at 52-Week Highs
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.